Construction method of VASP gene knockout cell line

The construction of VASP gene knockout cell line through CRISPR/Cas9 technology solved the problem of studying the mechanism of action of VASP protein, realized the effective knockout and expression verification of VASP protein, and provided important research for understanding the mechanism of actin regulation and viral infection. tool.

CN118979059APending Publication Date: 2024-11-19LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411031109.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively study the mechanism of VASP proteins in cells, especially in viral infection and intercellular transmission, and there is a lack of VASP knockout cell lines to understand the fundamental molecular pathways for actin regulation.

Method used

The VASP gene knockout cell line was constructed by CRISPR/Cas9 technology. The expression inactivation of VASP protein and the expression inactivation of VASP protein were verified by designing sgRNA, connecting with PX459 vector, transfecting cells, and using puromycin to screen the cells, and the expression inactivation of VASP protein and Stability of knockout.

Benefits of technology

The VASP knockout cell line was successfully constructed, the expression inactivation of VASP protein was verified, and a tool was provided for studying VASP functions and related pathways, with the characteristics of simplicity, efficiency, speed and low cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979059A_ABST
    Figure CN118979059A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of gene engineering, in particular to a construction method of a porcine VASP gene knockout cell line. The method comprises the following steps: synthesizing guide RNA with a restriction enzyme cutting site aiming at a VASP gene and a complementary sequence of the guide RNA, connecting the sgRNA and the complementary sequence of the sgRNA into a double-stranded sgRNA fragment by utilizing a base complementary pairing principle, constructing a recombinant CRISPR / Cas9 plasmid by virtue of a molecular cloning recombination technology, transfecting the plasmid into a porcine lung epithelial cell, designing an sgRNA primer, screening a positive single-cell cloned strain by virtue of a puromycin drug, and carrying out screening by virtue of a puromycin drug so as to obtain the single-cell cloned strain. DNA and protein of the single-cell clone strain are extracted, VASP gene sequencing and protein expression detection are carried out, and finally the PPE cell with the VASP gene knocked out is obtained. The method has the characteristics of simplicity, high efficiency, rapidness, low cost and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of genetic engineering, and in particular to a method for constructing a VASP gene knockout cell line. Background Art

[0002] Actin is the most abundant protein in many eukaryotic cells. Actin is a globular monomer of G-actin, which, when polymerized, forms F-actin, a filamentous structure that can form spontaneously under physiological conditions. Actin filaments play an important role in many cellular processes, including motility, morphogenesis, cytokinesis or endocytosis. Actin bundling proteins can cross-link actin filaments into actin bundles, which are the main components of the actin network. Inside the cell, the forces exerted by actin are generated by myosin molecular motors that move along long actin domains, called stress fibers. These stress fibers are often anchored to adhesions corresponding to complex structures that are responsible for interacting with the key scaffolds of actin.

[0003] Ena / VASP proteins are a family of conserved actin regulatory proteins composed of EVH1, EVH2 domains and a proline-rich central region. They have been implicated in actin-based processes such as fibroblast migration, axon guidance, and T-cell polarization, and are important for actin motility of intracellular pathogens. Mechanistically, these proteins bind to the barbed ends of actin filaments and antagonize filament capping by capping protein (CapZ). Furthermore, they reduce the density of Arp2 / 3 complex-dependent actin filament branches and bind Profilin at sites of actin polymerization. These findings define Ena / VASP proteins as multifunctional organizers of the actin cytoskeleton. Vasodilator-stimulated phosphoprotein (VASP), a founding member of the Ena / VASP family, was independently discovered as a protein phosphorylated in platelets in response to drugs that elevate cAMP and cGMP, and VASP mutant mice display defects in the actin-dependent process of platelet aggregation. In vitro results showed that VASP reduced the number of F-actin branches induced by Listeria ActA and Arp2 / 3 complex. However, another study did not find any effect of VASP on branches.

[0004] One function of VASP is to bind and recruit Profilin, an actin monomer-binding protein that itself promotes barbed-end polymerization. In addition, recent studies have shown that VASP promotes the release of branched connections of the Arp2 / 3 complex from ActA, which may accelerate motility by allowing faster growth of the actin network on the bacterial surface. In addition, VASP appears to affect the geometry of the network formed by the Arp2 / 3 complex. In particular, VASP reduces the frequency of y-branch formation, and recent studies have shown that VASP increases the proportion of parallel-aligned filaments in comet tails formed by actin filaments in vitro. Interaction with VASP is important in pathogenesis, as ActA mutants that do not interact with VASP exhibit altered motility parameters such as directionality and persistence and are defective in cell-to-cell spread and virulence in mice. The actin-binding protein VASP, like the Arp2 / 3 complex, is also localized to the entire actin tail. In cells lacking VASP, tails are also formed normally, suggesting that these proteins are not essential for actin polymerization. Fibroblasts lacking the lamellipodia Ena / VASP protein exhibited abnormally short and branched actin filaments, whereas overexpression of Ena / VASP resulted in longer and less branched filaments.

[0005] The actin cytoskeleton plays a very important role in virus dynamics and formation and spread. Therefore, some viruses disrupt the actin cytoskeleton to enable long-distance spread and movement. PRV has been reported to induce long and often branched actin-containing cellular protrusions. These cellular protrusions establish close contacts with neighboring cells, and viral particles migrate toward the tip in the protrusions. Inhibition of actin rearrangements using the actin-stabilizing drug jasplakinolide significantly reduced the antibody-resistant cell-to-cell spread of PRV, suggesting that this process plays a very important role in enhancing cell-to-cell viral spread. And similar virus-induced cellular projections have also been reported in HSV-1 and VZV. The late stages of the herpes virus replication cycle are also associated with the disassembly of actin stress fibers, cell rounding, and the formation of actin-containing cellular protrusions. These cellular protrusions may be associated with enhanced viral cell-to-cell spread.

[0006] VASP has an important influence on the formation of cell protrusions and branches, so the role of VASP in the mechanism of viral infection is crucial.

[0007] The role and mechanism of virus using cell protrusions for intercellular transmission in viral infection is becoming an emerging research direction. Based on CRISPR / Cas9 knockout technology, a porcine VASP gene knockout cell line was constructed to increase our understanding of how pathogens use actin and reveal the basic molecular pathways involved in actin regulation in host cells. Summary of the invention

[0008] In order to solve the above problems, the present invention provides a method for constructing a VASP gene knockout cell line.

[0009] In order to achieve the above object, the present invention provides the following technical solutions:

[0010] The present invention provides a method for constructing a VASP gene knockout cell line, comprising the following steps:

[0011] 1) Add the sticky ends of Bbs1 restriction endonuclease and adapter to the sgRNA to obtain the insert fragment;

[0012] The nucleotide sequence of the sgRNA is shown in SEQ ID No. 1;

[0013] 2) annealing the inserted fragment obtained in step 1) and its complementary sequence to obtain a double-stranded fragment;

[0014] The nucleotide sequence of the complementary sequence is shown in SEQ ID No.4;

[0015] 3) connecting the double-stranded fragment obtained in step 2) with the PX459 vector, transforming the obtained ligation product into competent Escherichia coli, extracting the plasmid, and obtaining the recombinant plasmid PX459M-VASP-sgRNA;

[0016] The PX459 vector was digested with Bbs1 enzyme;

[0017] 4) mixing the recombinant plasmid PX459M-VASP-sgRNA obtained in step 3) with Lip2000 liposomes and PPE cells, and transfecting the mixture to obtain transfected cells;

[0018] 5) The transfected cells obtained in step 4) are subjected to puromycin screening for positive single cell clones to obtain a PPE cell line with VASP gene knockout.

[0019] Preferably, the linker in step 1) is CACCG, and the nucleotide sequence of the inserted fragment is shown in SEQ ID No.3.

[0020] Preferably, the annealing system in step 2) is: 13.5 μL of the insert fragment with a concentration of 10 μM, 13.5 μL of the complementary sequence with a concentration of 10 μM, and 3 μL of 10×PCRBuffer;

[0021] The annealing conditions are: annealing at 99° C. for 5 minutes.

[0022] Preferably, the enzyme digestion system in step 3) is: 2 μg of PX459 vector, 2 μL of Bbs1 enzyme, 5 μL of 10×buffer G, and ddH2O is added to make up the system to 50 μL; the enzyme digestion conditions are: reacting in a 37° C. water bath for 2 to 4 hours.

[0023] Preferably, the system for connection in step 3) is: 50 ng of PX459 vector, 0.5 μL of 10×T4 buffer, 2 μL of double-stranded fragment, 0.5 μL of T4 DNAligase, and ddH2O is added to make up the system to 5 μL;

[0024] The connection conditions are: reaction at 16°C for 1 hour.

[0025] Preferably, in step 4), the ratio of the mass of the recombinant plasmid PX459M-VASP-sgRNA to the volume of Lip2000 liposomes and the number of PPE cells is 1 μg: 2 μL: 1×10 6 indivual.

[0026] Preferably, the transfection time in step 4) is 24 hours.

[0027] Preferably, the concentration of puromycin used in step 5) is 1.5-2.5 μg / mL.

[0028] Preferably, the concentration of puromycin used in step 5) is 2 μg / mL.

[0029] Preferably, the puromycin is mixed with a complete culture medium and then screened, the puromycin culture medium is changed once every 2 days, and the screening time is 4 days.

[0030] The beneficial effects of the present invention are:

[0031] 1. The present invention successfully constructed a VASP gene knockout PPE cell line in which VASP protein expression was inactivated due to the deletion of VASP gene fragments.

[0032] 2. The present invention utilizes the CRISPR-Cas9 system, and through gene sequencing identification and protein immunoblotting verification, it is determined that a VASP gene knockout PPE cell line was successfully constructed.

[0033] 3. The VASP gene knockout constructed by the present invention can be stably inherited to daughter cells along with cell proliferation and division.

[0034] 4. The PX459-VASP-sgRNA plasmid constructed by the present invention has puromycin resistance. Adding puromycin to screen cells is beneficial to improving the positive rate of obtaining VASP gene knockout single cell clones.

[0035] 5. The present invention can be used for targeted knockout of the VASP gene, and has the characteristics of simplicity, high efficiency, rapidity, and low cost, and is of great significance for the study of VASP gene function and related pathways. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.

[0037] Figure 1 It is the sequencing comparison result of the VASP gene of the single cell clone after the PX459-VASP-sgRNA plasmid of the present invention was transfected into PPE cells;

[0038] Figure 2 The Western-Blotting detection results of VASP protein expression in the primary single-cell clone after the PX459-VASP-sgRNA plasmid of the present invention was transfected into PPE cells;

[0039] Figure 3 The Western-Blotting detection results of VASP protein expression in F10 generation single cell clones after PX459-VASP-sgRNA plasmid of the present invention was transfected into PPE cells;

[0040] Figure 4 The immunofluorescence detection results of VASP protein in single cell clones after the PX459-VASP-sgRNA plasmid of the present invention was transfected into PPE cells;

[0041] Figure 5 This is a microscopic image of a single-cell clone of PPE cells after VASP gene knockout of the present invention. DETAILED DESCRIPTION

[0042] The present invention provides a method for constructing a VASP gene knockout cell line, comprising the following steps:

[0043] 1) Add the sticky ends of Bbs1 restriction endonuclease and adapter to the sgRNA to obtain the insert fragment;

[0044] The nucleotide sequence of the sgRNA is shown in SEQ ID No. 1;

[0045] 2) annealing the inserted fragment obtained in step 1) and its complementary sequence to obtain a double-stranded fragment;

[0046] The nucleotide sequence of the complementary sequence is shown in SEQ ID No.4;

[0047] 3) connecting the double-stranded fragment obtained in step 2) with the PX459 vector, transforming the obtained ligation product into competent Escherichia coli, extracting the plasmid, and obtaining the recombinant plasmid PX459M-VASP-sgRNA;

[0048] The PX459 vector was digested with Bbs1 enzyme;

[0049] 4) mixing the recombinant plasmid PX459M-VASP-sgRNA obtained in step 3) with Lip2000 liposomes and PPE cells, and transfecting the mixture to obtain transfected cells;

[0050] 5) The transfected cells obtained in step 4) are subjected to puromycin screening for positive single cell clones to obtain a PPE cell line with VASP gene knockout.

[0051] In the present invention, the sticky end and linker of the Bbs1 restriction endonuclease are added to the sgRNA to obtain an insert fragment; the nucleotide sequence of the sgRNA is shown in SEQ ID No. 1, which is as follows:

[0052] GTACTTGACACCCCGGACGA.

[0053] In the present invention, the linker is preferably CACCG, and the nucleotide sequence of the insert is shown in SEQ ID No. 3, specifically as follows:

[0054] 5'-CACCGGTACTTGACACCCCGGACGA.

[0055] The present invention anneals the obtained insert fragment and its complementary sequence to obtain a double-stranded fragment; the nucleotide sequence of the complementary sequence is shown in SEQ ID No.4, which is as follows:

[0056] 5'-AAACTCGTCCGGGGTGTCAAGTACC.

[0057] In the present invention, the annealing system is preferably: 13.5 μL of an insert fragment with a concentration of 10 μM, 13.5 μL of a complementary sequence with a concentration of 10 μM, and 3 μL of 10×PCR Buffer. In the present invention, the annealing conditions are preferably: annealing at 99° C. for 5 min.

[0058] The present invention connects the obtained double-stranded fragment with the PX459 vector, transforms the obtained connection product into competent Escherichia coli, extracts the plasmid, and obtains the recombinant plasmid PX459M-VASP-sgRNA; the PX459 vector is digested by Bbs1 enzyme. In the present invention, the digestion system is preferably: PX459 vector 2μg, Bbs1 enzyme 2μL, 10×buffer G 5μL, and ddH2O is added to make up the system to 50μL. In the present invention, the digestion conditions are preferably: react in a 37°C water bath for 2 to 4h. In the present invention, the connection system is preferably: PX459 vector 50ng, 10×T4 buffer 0.5μL, double-stranded fragment 2μL, T4 DNAligase0.5μL, and ddH2O is added to make up the system to 5μL. In the present invention, the connection conditions are preferably: react at 16°C for 1h.

[0059] The present invention mixes the obtained recombinant plasmid PX459M-VASP-sgRNA with Lip2000 liposomes and PPE cells, and transfects them to obtain transfected cells. In the present invention, the mass of the recombinant plasmid PX459-VASP-sgRNA to the volume of the Lip2000 liposomes and the number of PPE cells is preferably 1 μg: 2 μL: 1×10 6 In the present invention, the transfection time is preferably 24h.

[0060] The present invention uses puromycin to screen positive monoclonal cell lines of the obtained transfected cells to obtain a PPE cell line with VASP gene knockout. In the present invention, the concentration of the puromycin used is preferably 1.5-2.5 μg / mL. In the present invention, the concentration of the puromycin used is preferably 2 μg / mL. In the present invention, the puromycin is mixed with a complete culture medium and then screened, and the puromycin culture medium is changed once every 2 days, and the screening time is 4 days.

[0061] In order to further illustrate the present invention, the present invention is described in detail below in conjunction with embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0062] Example 1

[0063] Vector construction

[0064] 1). Design of sgRNA for VASP gene

[0065] For the VASP gene (gene name: VASP, gene ID number: 110261011, for detailed gene information, see https: / / www.ncbi.nlm.nih.gov / gene / 110261011), the porcine VASP genome sequence was retrieved from the Genebank website.

[0066] In the mRNA introduction, there are a total of 9 predicted porcine sequences, combined with the mRNA sequences with full coverage of the selected fragments, to find and download the gene coding region sequences. (For details of mRNA information, see https: / / www.ncbi.nlm.nih.gov / nuccore / XM_021094559.1).

[0067] sgRNA was designed using online software (http: / / crispor.tefor.net / ), the above gene coding region sequence was input, several sgRNA sequences were set and retrieved, and the position of sgRNA on the gene sequence and the off-target information of the sgRNA were analyzed to select an optimal sgRNA sequence, as shown in Seq-1, as shown in Table 1:

[0068] Table 1 Target sequences

[0069] Serial Number name Target sequence SEQ ID No.1 Seq-1 GTACTTGACACCCCGGACGA SEQ ID No.2 Seq-2 TCGTCCGGGGTGTCAAGTAC SEQ ID No.3 Seq-3 CACCGGTACTTGACACCCCGGACGA SEQ ID No.4 Seq-4 AAACTCGTCCGGGGTGTCAAGTACC

[0070] 2) Synthesize sgRNA double-stranded fragments and anneal

[0071] The sgRNA designed above is to be cloned into the PX459 vector. The sgRNA sequence is added with the sticky end of the Bbs1 restriction endonuclease and sent to the bioengineering biosynthetic single nucleotide chain.

[0072] Add a linker to the Seq-1 sequence to synthesize the insert fragment VASP-sgRNA:

[0073] Seq-1F: 5'-CACCGGTACTTGACACCCCGGACGA (SEQ ID No. 3);

[0074] Seq-1R: 5'-AAACTCGTCCGGGGTGTCAAGTACC (SEQ ID No. 4);

[0075] Seq-1F and Seq-1R were mixed in equal volumes for annealing reaction. The annealing reaction system included 13.5 μL of each primer shown in Seq-1F and Seq-1R at a concentration of 10 μM and 3 μL of 10×PCRBuffer. The mixture was placed in a PCR instrument for reaction at 99°C for 5 min and 4°C for ∞. The double-stranded fragment of sgRNA was obtained, which could be connected to the restriction vector or stored at -20°C for later use.

[0076] 3) Enzyme digestion and gel recovery of PX459 vector

[0077] Take 2μg of PX459 vector and digest it with Bbs1. The digestion system is: PX459 2μg, Bbs1 2μL, 10× buffer G 5μL, add ddH2O to make up the system to 50μL. Mix well and react in a 37℃ water bath for 2-4 hours. Use agarose DNA recovery kit to recover and purify the above digestion products. For specific experimental steps, see the instructions of the agarose DNA recovery kit.

[0078] 4) Ligation of VASP-sgRNA double-stranded fragment and PX459 vector

[0079] In a 1.5mL EP tube, add 50ng of the PX459 vector after enzyme digestion, 0.5μL of 10×T4 buffer, 2μL of VASP-sgRNA double-stranded fragment, and 0.5μL of T4 DNAligase. Add ddH2O to make up the system to 5μL. Mix well and react in a ligator at 16℃ for 1h. Store at 4℃ for later use.

[0080] 5) Ligation product transformation and PCR identification

[0081] The above ligation product was added to 50uL competent bacteria and placed on ice for 30min; heat-shocked in a 42°C water bath for 90s and then placed on ice for 3min; 1ml of non-resistant LB medium was added and the culture was restored in a 37°C shaker for one hour; the bacterial solution was centrifuged at 3000rpm for 20s, the supernatant was discarded, and the remaining 100ul liquid was resuspended and mixed; the bacterial solution was spread on an ampicillin-resistant plate and placed in a 37°C constant temperature incubator for overnight culture; a single colony was picked for expansion culture, the recombinant plasmid was extracted after the bacterial solution was harvested, and then sequenced and identified, and the correctly identified recombinant plasmid PX459M-VASP-sgRNA was saved.

[0082] Example 2

[0083] Preparation of VASP gene knockout PPE cell line

[0084] 1. PX459M-VASP-sgRNA transfection of PPE cells

[0085] 1) Cells were inoculated into 12-well plates. PPE cell suspension (from Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences) was taken and the suspension was adjusted to 1×10 6 Inoculate the cells at the same number per well and evenly spread them into one well of a 12-well plate. Add complete culture medium (containing 5% fetal bovine serum and 1% double antibody) to 1 mL and place in a cell culture incubator for 12-16 hours.

[0086] 2) Take out two sterile EP tubes and add 100 μL Opti-DMEM culture medium to each of them. Add 1 μg of PX459M-VASP-sgRNA recombinant plasmid to the first sterile EP tube, which is called liquid A; add 2 μL Lip2000 liposomes to the second sterile EP tube and mix well, which is called liquid B.

[0087] 3) Gently add liquid B to liquid A, mix evenly (blowing 3-5 times with a gun), and let stand at room temperature for 25 minutes;

[0088] 4) Gently add the A / B mixture dropwise into the corresponding 12-well plate, gently shake the cell culture plate back and forth, and then return the 12-well plate to the cell culture incubator for further culturing for 24 hours.

[0089] 2. Puromycin drug screening

[0090] 1) 24 hours after transfection, the cells were digested with trypsin and divided into three parts. 1 mL of culture medium with different final concentrations of puromycin (final concentrations of 1.5 ug / mL, 2 ug / mL, and 2.5 ug / mL) was added to each part and mixed by pipetting. Each concentration of cells was matched with a wild-type cell (WT cell) that was not transfected as a control.

[0091] 2) The medium was changed every two days, with WT cells as the control. The screening was stopped when all WT cells died. The screening was usually completed in 4 days.

[0092] 3) After the screening is stopped, the culture medium is replaced, generally with 10% complete culture medium, and the culture is continued for 3-4 days. After the transfected cells recover and grow a small amount, proceed to the next step.

[0093] 3. Target gene targeting detection

[0094] 1) Digest the selected cells with trypsin and collect 50% of the cells;

[0095] 2) Extract the genome of the cells using a genome extraction kit;

[0096] 3) Using the extracted cell genomic DNA as a template, perform PCR amplification with the following primers:

[0097] seq-2F: TATTTTCGATGAGTCCACTGAG (SEQ ID No. 5);

[0098] seq-2R: CACTGTGATGCTCTATGATGACA (SEQ ID No. 6);

[0099] The PCR reaction system included 25 μL of 2×Taq Master Mix, 2 μL of each primer shown in Seq-2F ​​and Seq-2R at a concentration of 10 μM, 0.1 μg of template DNA, and ddH2O to make up the system to 50 μL; the PCR reaction program was 95°C pre-denaturation reaction for 3 min; 95°C denaturation reaction for 15 s, 60°C annealing reaction for 15 s, 72°C extension reaction for 45 s, 35 cycles; 72°C extension for another 5 min;

[0100] 4) Perform agarose gel electrophoresis on the amplified product, observe the size of the amplified product band, and sequence the PCR product for identification.

[0101] 4. Cell monoclonal culture

[0102] 1) Take 400 cells after screening in step 1) of step 3, add them into 20 mL of complete culture medium, and mix by pipetting;

[0103] 2) The cell suspension was plated into two 96-well culture plates using a spray gun, 100 μL / well;

[0104] 3) After culturing the cells for 4 hours, observe the cell growth under a microscope and mark single cell clones.

[0105] 5. Single cell clone gene level verification

[0106] 1) When the density of single-cell clones grows to 50%-60% of the area at the bottom of the well, use trypsin to digest the cells, take out 50% of the cells into an EP tube, extract the cell genome for gene sequencing verification, and continue to culture and amplify the remaining 50% of the cells in a 24-well plate;

[0107] [2] Using the extracted cell genomic DNA as a template, PCR amplification was performed using the following primers:

[0108] seq-2F: TATTTTCGATGAGTCCACTGAG (SEQ ID No. 5);

[0109] seq-2R: CACTGTGATGCTCTATGATGACA (SEQ ID No. 6);

[0110] The PCR reaction system included 25 μL of 2×Taq Master Mix, 2 μL of each primer shown in Seq-F and Seq-R at a concentration of 10 μM, 0.1 μg of template DNA, and ddH2O to make up the system to 50 μL; the PCR reaction program was 95°C pre-denaturation reaction for 3 min; 95°C denaturation reaction for 15 s, 60°C annealing reaction for 15 s, 72°C extension reaction for 45 s, 35 cycles; 72°C extension for another 5 min;

[0111] 4) The amplified products were detected by agarose gel electrophoresis to observe the band size of the amplified products, and the amplified products were sequenced for identification. After the positive cells were confirmed by sequencing comparison, the positive cells were expanded and cultured, and cryopreserved and named PPE-VASP-KO. The sequencing result comparison chart is shown.

[0112] 6. Western Blot detection of VASP protein expression in single cell clones

[0113] In order to verify the knockout effect of the VASP gene, we used Western Blot experiments to detect the expression of VASP protein in the VASP gene knockout PPE cell line.

[0114] 1) Cell collection: PPE-VASP-KO single cell clones and normal PPE cells were digested with trypsin, collected into 1.5 mL centrifuge tubes, centrifuged and discarded the supernatant, retaining the cell pellet;

[0115] 2) Cell lysis: Add NP-40 containing protease and phosphatase inhibitors to lyse the cells, lyse on ice for 10 minutes, centrifuge at 13000r / min for 15 minutes, take the supernatant into a new 1.5mL centrifuge tube, and measure the protein concentration;

[0116] 3) Sample preparation: Mix the total cell protein supernatant with 5× SDS protein loading buffer at a ratio of 4:1 and boil at 95°C for 5 min;

[0117] 4) Electrophoresis: Prepare 12% SDS-PAGE gel and perform electrophoretic separation of proteins. When concentrating the gel, the voltage is 80V and the time is 30 minutes. When separating the gel, the voltage is 120V and the time is 1 hour.

[0118] 5) Transfer: Wet transfer method, constant voltage 100V, transfer for 1.5 hours;

[0119] 6) Blocking: Use TBST solution with a final concentration of 5% skim milk powder and incubate the membrane at room temperature for 2 hours;

[0120] 7) Primary antibody incubation: The primary antibody VASP mAb (CST) was diluted 1:2000 in a TBST solution with a final concentration of 5% skim milk powder and incubated at 4°C overnight;

[0121] 8) Secondary antibody incubation: Wash the membrane three times with TBST, 10 minutes each time; dilute Peroxidase-AffiniPureDonkeyAnti-Goat IgG (H+L) (Jackson: 705-035-147) 1:5000 in a TBST solution with a final concentration of 5% skim milk powder, and incubate at room temperature for 1 hour.

[0122] 9) Exposure imaging: Wash the membrane three times with TBST, 10 minutes each time. Take equal amounts of chemiluminescent HRP (ECLWBKLS0500) colorimetric solution A and solution B, mix them evenly, and use a gel imaging instrument to image.

[0123] The results showed that VASP protein signals existed in PPE wild cells, but no VASP protein signals were detected in PPE-VASP-KO single cell clones, indicating that the single cell clone achieved VASP gene knockout at the protein level.

[0124] The present invention utilizes the VASP gene knockout PPE cell line constructed by the CRICPR / Cas9 system to edit the VASP gene at the DNA level, completely silencing the expression of the VASP protein, and providing a practical tool for the study of VASP gene function.

[0125] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A method for constructing a VASP gene knockout cell line, characterized in that: The following steps are involved: 1) Add the sticky ends of Bbs1 restriction endonuclease and adapter to the sgRNA to obtain the insert fragment; The nucleotide sequence of the sgRNA is shown in SEQ ID No. 1; 2) annealing the inserted fragment obtained in step 1) and its complementary sequence to obtain a double-stranded fragment; The nucleotide sequence of the complementary sequence is shown in SEQ ID No.4; 3) connecting the double-stranded fragment obtained in step 2) with the PX459 vector, transforming the obtained ligation product into competent Escherichia coli, extracting the plasmid, and obtaining the recombinant plasmid PX459M-VASP-sgRNA; The PX459 vector was digested with Bbs1 enzyme; 4) mixing the recombinant plasmid PX459M-VASP-sgRNA obtained in step 3) with Lip2000 liposomes and PPE cells, and transfecting the mixture to obtain transfected cells; 5) The transfected cells obtained in step 4) are subjected to puromycin screening for positive single cell clones to obtain a PPE cell line with VASP gene knockout.

2. The construction method according to claim 1, characterized in that: The linker in step 1) is CACCG, and the nucleotide sequence of the inserted fragment is shown in SEQ ID No.

3.

3. The construction method according to claim 1, characterized in that: The annealing system in step 2) is: 13.5 μL of the insert fragment with a concentration of 10 μM, 13.5 μL of the complementary sequence with a concentration of 10 μM, and 3 μL of 10×PCR Buffer; The annealing conditions are: annealing at 99° C. for 5 minutes.

4. The construction method according to claim 1, characterized in that: The enzyme digestion system of step 3) is: 2 μg of PX459 vector, 2 μL of Bbs1 enzyme, 5 μL of 10×buffer G, and ddH2O is added to make up the system to 50 μL; the enzyme digestion conditions are: react in a 37° C. water bath for 2 to 4 hours.

5. The construction method according to claim 1, characterized in that: The ligation system in step 3) is: 50 ng of PX459 vector, 0.5 μL of 10×T4 buffer, 2 μL of double-stranded fragment, 0.5 μL of T4 DNA ligase, and ddH2O is added to make up the system to 5 μL; The connection conditions are: reaction at 16°C for 1 hour.

6. The construction method according to claim 1, characterized in that: In step 4), the ratio of the mass of the recombinant plasmid PX459M-VASP-sgRNA to the volume of Lip2000 liposomes and the number of PPE cells is 1 μg: 2 μL: 1×10 6 indivual.

7. The construction method according to claim 1, characterized in that: The transfection time in step 4) is 24 hours.

8. The construction method according to claim 1, characterized in that: The concentration of puromycin used in step 5) is 1.5-2.5 μg / mL.

9. The construction method according to claim 8, characterized in that: The concentration of puromycin used in step 5) is 2 μg / mL.

10. The construction method according to claim 8 or 9, characterized in that: The puromycin was mixed with complete culture medium for screening, and the puromycin culture medium was changed once every 2 days. The screening time was 4 days.

Citation Information

Patent Citations

  • Clonal strains of attenuated vaccinia viruses and methods of use thereof

    CA2836299A1

  • Use of vasodilator-stimulated phosphoprotein in preparing medicine for preventing and treating lung cancer and breast cancer

    CN101361964A

  • Construction of KLHL34 knockout cell line and application of KLHL34 knockout cell line as small RNA viridae virus production cell line

    CN116445486A

  • Compounds, targets, and methods for modulating lytic granule convergence in cytotoxic cells to promote bystander killing in cellular therapies

    WO2023183525A1